title: Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.
abstract: OBJECTIVE
  To investigate 12-month outcomes of conversion to aflibercept in patients with neovascular age-related macular degeneration resistant to ranibizumab.
  
  
  METHODS
  Twenty-two eyes of 19 consecutive patients received 3 monthly aflibercept injections followed by a pro re nata protocol. Spectral-domain optical coherence tomography (OCT) images were obtained before each injection. All 49 cross-sectional OCT B-scans obtained in each examination were investigated and the largest choroidal neovascularization (CNV) size was chosen. The same cross-sectional B-scan sections containing the maximum CNV size were used during the follow-up.
  
  
  RESULTS
  After 12 months, best-corrected visual acuity increased from 45.68 ± 20.25 to 59.09 ± 17.50 Early Treatment Diabetic Retinopathy Study letters (p&lt;0.001), central subfield thickness decreased from 399.91 ± 148.85 to 304.55 ± 97.89 μm (p = 0.003), area of CNV declined from 0.38 ± 0.24 to 0.28 ± 0.19 mm2 (p = 0.003), and macular volume improved from 9.64 ± 1.75 to 8.45 ± 0.98 mm3 (p&lt;0.001). There was a significant resolution of intraretinal fluid (p = 0.016), but reduction of subretinal fluid was not significant (p = 0.25).
  
  
  CONCLUSIONS
  Visual and anatomic improvement were obtained after conversion to aflibercept.
authors: Department of Ophthalmology, University Eye Hospital, Hannover Medical School, Hannover - Germany.|Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran - Iran.
authors: Kaveh Abri
authors: KA
authors: Aghdam
authors: Department of Ophthalmology, University Eye Hospital, Hannover Medical School, Hannover - Germany.
authors: Amelie
authors: A
authors: Pielen
authors: Department of Ophthalmology, University Eye Hospital, Hannover Medical School, Hannover - Germany.
authors: Carsten
authors: C
authors: Framme
authors: Department of Ophthalmology, University Eye Hospital, Hannover Medical School, Hannover - Germany.
authors: Bernd
authors: B
authors: Junker
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003930:Diabetic Retinopathy / Q000188:drug therapy; D057915:Drug Substitution; D005123:Eye; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab